Drug Discovery World

FEBRUARY 23, 2024

The US Food and Drug Administration (FDA) has approved AstraZeneca’s osimertinib (Tagrisso) as a treatment for locally advanced or metastatic non-small cell lung cancer (la/mNSCLC). The FDA review was conducted under Project Orbis, which provides a framework for concurrent submission and review of oncology drugs among international partners.

Therapies 130

Therapies FDA Trials Treatment 130

Drug Discovery World

APRIL 11, 2023

Owing to the complexity of severe asthma, many patients have unclear or multiple drivers of airway inflammation resulting in some patients not responding to the current standard of treatment, and being at increased risk of asthma attacks, hospitalisations, and a poor quality of life 3,4,5,6. to 0.53; P<0.001).3 to 0.53; P<0.001).3

Treatment 246

Treatment Clinical Trials Trials Science 246

Drug Discovery World

MARCH 2, 2023

DDW’s Diana Spencer reports on the recent Avacta Therapeutics Science Day, which explored the latest exciting developments in targeted treatments for cancer and asked what advances the future might bring. She explained the mechanism by which AVA6000 can provide more precise treatment than current chemotherapies.

Therapies 130

Therapies Treatment Trials Disease 130

Drug Discovery World

NOVEMBER 14, 2023

Takeda’s Adzynma has become the first recombinant protein product approved in the US for prophylactic or on-demand enzyme replacement therapy (ERT) for congenital thrombotic thrombocytopenic purpura (cTTP). Without treatment, cTTP is ultimately fatal.

Therapies 130

Therapies FDA Approval Protein Production FDA 130

Drug Discovery World

NOVEMBER 17, 2023

Arcellx entered a global strategic collaboration with Kite Pharma in December 2022 to co-develop and co-commercialise CART-ddBCMA for the treatment of this patient group. Just 38 patients were evaluable for efficacy and safety analysis in June 2023 based on a median follow-up of 22 months following treatment.

Trials 130

Trials International Therapies Treatment 130

Drug Discovery World

DECEMBER 13, 2022

A novel, patient-tailored monoclonal antibody therapy has shown promise in treating moderate to severe atopic dermatitis. . Patients who participated in a clinical trial of rocatinlimab showed positive results while taking the drug and up to 20 weeks after stopping therapy, Mount Sinai researchers have reported in The Lancet. .

Treatment 130

Treatment Clinical Trials Laboratories Therapies 130

SCIENMAG: Medicine & Health

JUNE 15, 2023

A new therapy is on the horizon for patients with metastatic colorectal cancer who have run out of treatment options. Credit: Vanderbilt University Medical Center A new therapy is on the horizon for patients with metastatic colorectal cancer who have run out of treatment options.

Treatment 83

Treatment Clinical Trials International Therapies 83

Drug Discovery World

MAY 10, 2024

A leading news story this week has been the announcement of positive Phase II results of a head and neck cancer trial, but there have been a number of other interesting clinical result announcements. The post This week in drug discovery (6-10 May) appeared first on Drug Discovery World (DDW).

Drugs 173

Drugs Trials Therapies International 173

Drug Target Review

AUGUST 28, 2024

What are the main challenges currently faced in the treatment of chronic liver diseases, and how does Resolution Therapeutics aim to address these challenges? Once a patient develops advanced cirrhosis/end-stage liver disease there are no specific therapies to significantly avoid major decompensations and death in the next few years.

Therapies 114

Therapies Disease Engineering Medical Schools 114

Drug Discovery World

SEPTEMBER 27, 2024

The efficacy of the treatment was evaluated in the IMROZ trial in patients with newly diagnosed multiple myeloma who were not eligible for ASCT. The main efficacy outcome measure was progression-free survival (PFS) as assessed by an independent review committee based on International Myeloma Working Group criteria.

FDA Approval 130

FDA Approval FDA International Treatment 130

Drug Discovery World

JULY 19, 2023

Safety and efficacy TRAILBLAZER-ALZ 2, a randomised, double-blind, placebo-controlled study, evaluated the safety and efficacy of donanemab, an investigational amyloid plaque targeting therapy. 52% of participants completed their course of treatment by one year and 72% completed by 18 months as a result of achieving plaque clearance.

Disease 130

Disease Trials Clinical Trials Therapies 130

Drug Discovery World

AUGUST 2, 2023

Renaissance Pharma has announced its first development programme focused on Hu14.18, a humanised anti-GD2 monoclonal antibody (mAb), licensed from St Jude Children’s Research Hospital for the treatment of newly diagnosed high-risk neuroblastoma. A novel Phase II trial incorporating Hu14.18 A novel Phase II trial incorporating Hu14.18

Licensing 246

Licensing Licensing Hospitals Therapies 246

Drug Discovery World

AUGUST 6, 2024

Centogene has announced data from its Rostock International Parkinson’s Disease (ROPAD) Study revealing the genetic factors and prevalence of Parkinson’s disease (PD). The findings from the study indicate that approximately 15% of PD-related cases are tied to genetic variants, with the majority being linked to LRRK2 and GBA1.

Clinical Trials 162

Clinical Trials Disease International Trials 162

Drug Discovery World

JULY 5, 2024

Newron Pharmaceuticals has reported new findings of mechanism of action that indicate its drug candidate evenamide could be uniquely effective in patients with treatment resistant schizophrenia (TRS). Furthermore, by acting at the site of pathology, evenamide might also be effective for negative symptoms and cognitive dysfunction.”

Pharmaceuticals 264

Pharmaceuticals Clinical Development International Therapies 264

Drug Discovery World

NOVEMBER 3, 2023

News round-up for 30 October – 3 November by DDW Editor Reece Armstrong My news highlights this week feature a variety of exciting clinical trial results and launches that are examining therapies for much-needed disease areas, new drug approvals and even a space mission with a pharma twist.

Clinical Trials 130

Clinical Trials Drugs Trials Therapies 130

Drug Discovery World

MAY 16, 2023

What are the global innovations in cell and gene therapy? What opportunities and challenges are emerging and can therapies get to market faster? Curbishley explains that as the wave of new therapies in development continues to increase, global pressures on manufacturing availability will become more acute. The solution?

Therapies 130

Therapies Clinical Trials Marketing Production 130

Common Sense for Drug Policy Blog

APRIL 21, 2024

Agonist Treatment for Cannabis Use Disorder "Cannabinoid agonist treatment is unlikely to be an approach relevant to all cannabis users seeking treatment, as evidenced by the large numbers of individuals who did not complete the study screening process, and the modest 12-week treatment retention rates. JAMA Intern Med.

Treatment 52

Treatment Clinical Trials International Therapies 52

Conversations in Drug Development Trends

APRIL 3, 2024

By: Sue Batchelor, Executive Director, Oncology Project Management Radiopharmaceuticals represent a cutting-edge frontier in oncology treatment, offering the promise of highly targeted therapy with the potential to revolutionize cancer care. Are you aware of the challenges you must address for a successful radiopharmaceutical trial?

Trials 81

Trials Clinical Trials Compliance Treatment 81

Conversations in Drug Development Trends

JANUARY 24, 2024

Written By: Derek Ansel, MS, CCRA, Executive Director, Therapeutic Strategy Lead, Rare Disease Given that 80% of rare diseases have a genetic etiology, genetic implications should be addressed at the onset of a clinical program to support trial enrollment. One diagnostic example that I discussed in my presentation is autism.

Trials 75

Trials Disease Clinical Trials Clinical Research 75

Drug Discovery World

FEBRUARY 2, 2024

Sunday 4 February is World Cancer Day, an international awareness day led by the Union for International Cancer Control (UICC), so the round-up this week will focus on oncology, including the UK approval of a rare blood cancer drug and a novel production process for CAR-T therapies.

Pharmacokinetics 130

Pharmacokinetics Drugs International Clinical Trials 130

Drug Discovery World

JUNE 28, 2023

Takeda has revealed favourable interim results from its Phase III crossover trial evaluating the safety and efficacy of TAK-755 (recombinant ADAMTS13) replacement therapy for the prophylactic treatment of congenital thrombotic thrombocytopenic purpura (cTTP). Acute TTP events have a mortality rate of >90%, if left untreated.

Trials 130

Trials Clinical Trials Drugs Therapies 130

Drug Discovery World

MAY 8, 2024

The ORCA-V1 trial was led by Achieve Life Sciences, and co-led by an investigator from Massachusetts General Hospital. In their previous clinical trial, the research team found that cytisinicline helped people to quit smoking traditional cigarettes. “The For cytisinicline treatment compared to placebo, 31.8% versus 15.1%

Clinical Trials 182

Clinical Trials Trials Compliance Drugs 182

Alta Sciences

SEPTEMBER 13, 2023

Four Pain Models Altasciences Uses to Assess Treatments During Clinical Trials pmjackson Wed, 09/13/2023 - 17:01 September is pain awareness month, and the importance of pain management and continued research into effective analgesics is integral to helping patients suffering from various pain conditions.

Clinical Trials 52

Clinical Trials Treatment Trials Drug Development 52

Drug Discovery World

MAY 10, 2024

Study 008A Study 008A was a four-week, international, randomised, double-blind and placebo-controlled add-on Phase II/III study performed in 45 centres in 11 countries in Europe, Asia and Latin America. 291 patients were randomised to treatment either with evenamide or placebo as add-on to their current antipsychotic therapy.

International 182

International Pharmaceuticals Treatment Trials 182

PPD

JUNE 7, 2023

The number of pediatric patients diagnosed with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) is on the rise, yet there are currently no approved therapies to treat NAFLD and NASH in adult or pediatric populations. As therapies for the treatment of NASH in adult patients go this year to the U.S.

Trials 98

Trials Clinical Trials Clinical Research Disease 98

Drug Discovery World

AUGUST 26, 2022

A treatment for Monkeypox, spider venom for drug discovery and funding for international start-ups are some of the stories in this week’s news round-up. A new study investigating a potential treatment for people who have been diagnosed with monkeypox has been launched by the same team who helped develop Covid-19 treatments.

International 130

International Drugs Clinical Trials Treatment 130

Drug Discovery World

SEPTEMBER 16, 2022

A slightly quieter week for news in light of national events in the UK, but the vital work of the international drug discovery community goes on and new discoveries are being made all the time. . First biologic therapy for young children with severe eczema . Trial sheds light on combined treatment for colorectal cancer .

FDA Approval 130

FDA Approval Drugs FDA Clinical Trials 130

Drug Discovery World

APRIL 25, 2023

University of California researchers have dosed the second participant in their clinical trial to identify a potential cure for HIV utilising CAR-T cell therapy. The trial is the first-in-human clinical study investigating the duo CAR-T cell therapy for the treatment of HIV. “We In 2021 there were an estimated 1.5

Research 130

Research Clinical Trials Therapies Clinical Development 130

Drug Discovery World

SEPTEMBER 7, 2023

1 There are a number of challenges faced in paediatric R&D, including the fact that the overall group includes five different age groups, the need for specific biomarkers, the extra length of time needed for trials, and the ethical concerns of conducting clinical trials in children.

Clinical Trials 147

Clinical Trials Trials Drugs DNA 147

Drug Discovery World

JULY 30, 2024

In new revelations about glucagon-like peptide-1 (GLP-1) drugs like Ozempic, a study has demonstrated the therapies could protect against dementia. The trial data was reported at the Alzheimer’s Association International Conference (AAIC) 2024, in Philadelphia, US.

Trials 130

Trials Clinical Trials Disease Science 130

Drug Discovery World

JANUARY 5, 2024

The top stories: China’s NMPA okays maribavir for post-transplant cytomegalovirus Takeda’s Livtencity (maribavir) has been approved in China for the treatment of adult patients with post-hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT) cytomegalovirus (CMV) infection/disease.

Drugs 130

Drugs International FDA Regulations 130

Drug Discovery World

JANUARY 11, 2024

Researchers have used messenger RNA (mRNA) to create an effective therapy for a rare liver disease in preclinical studies, demonstrating the technology’s potential therapeutic use in people. Successful industry/academia collaboration Fewer than 5% of rare diseases have approved therapies and most of these treatments use gene therapy.

Disease 147

Disease Research RNA Therapies 147

H1 Blog

SEPTEMBER 26, 2023

Breaking Down Barriers to International Clinical Trials Global Disruptions, Health Equity & Data Sharing As the U.S. Breaking Down Barriers to International Clinical Trials Global Disruptions, Health Equity & Data Sharing As the U.S. Additionally, clinical trials are no longer confined to one country or region.

Trials 59

Trials Clinical Trials International Regulations 59

Drug Discovery World

MAY 30, 2024

Unlike existing anti-obesity therapies that compromise lean muscle mass, ATR-127 induces significant weight loss while preserving crucial lean body mass. We are now advancing our next generation small molecules for the treatment of obesity to IND preparatory studies in H1 next year and expect to enter the clinic in 2026.”

Small Molecule 147

Small Molecule Treatment International Production 147

Drug Discovery Today

NOVEMBER 10, 2022

A team of surgeons and scientists from the UK, Sweden and Canada, funded by Rinri Therapeutics, has confirmed secure surgical access to the central core of the human cochlea The research, published in Scientific Reports, is critical to the first in-human trials of new cell, gene and drug therapies for the inner ear, and will assist with treatment for (..)

International 100

International Research Therapies Trials 100

Drug Discovery World

JULY 25, 2023

The US Food and Drug Administration (FDA) has approved Daiichi Sankyo’s quizartinib (Vanflyta) for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3 internal tandem duplication (ITD)-positive.

FDA Approval 130

FDA Approval FDA Clinical Trials Trials 130

Drug Discovery World

MARCH 21, 2023

Improved diagnostics Diagnostics and screening are essential to the early treatment of colorectal cancer. The researchers confirmed a clinical complete response in all 14 patients who received the immunotherapy treatment dostarlimab as a first-line treatment for mismatch repair-deficient (MMRd) locally advanced rectal cancer.

RNA 130

RNA Clinical Trials Drugs Therapies 130